| About the author: |
N. V. Kuzminova, A. V. Ivankova, S. E. Lozinsky, I. I. Knyazkova, A. O. Gavrylyuk, Yu. L. Shkarivskyi, O. M. Kulchytska |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
We examined 82 patients with stage II hypertension. 50 of them had frequent ventricular arrhythmias according to Holter electrocardiogram monitoring. 32 patients had verified stage II hypertension without any heart rhythm disorders, another 30 healthy individuals were included in the control group. It was found that in patients with ventricular arrhythmias, the level of apelin-13 was significantly (p<0.0001) lower than in healthy individuals and even in patients with hypertension but without arrhythmias. In turn, the level of cystatin C in patients with ventricular arrhythmias was significantly (p <0.001) higher than the corresponding level in patients with stage II hypertension without arrhythmias and in the control group. Patients with frequent ventricular arrhythmias also had more pronounced proatherogenic shifts in the blood lipid spectrum and higher levels of uric acid (p<0.05) compared with patients with hypertension of the second stage but without arrhythmias. In patients with stage II hypertension, a significant decrease in glomerular filtration rate was observed compared with control (p <0.001), while in patients with stage II hypertension and ventricular arrhythmias, the level of glomerular filtration rate (both by creatinine- and cystatin-calculated) not only the lowest but also less than 60 ml/min/1.73 m 2. |
| Tags |
apelin-13, cystatin C, glomerular filtration rate, metabolic cardiovascular risk factors |
| Bibliography |
- Zharinov OI, Talaieva TV, Lishchyshyna OM, Bozhko LI, Hetman TV, Zalevskyi VP, et al. Adaptovana klinichna nastanova, zasnovana na dokazakh. Fibryliatsiia peredserd. Rekomendatsii Robochoi hrupy z porushen rytmu sertsia Asotsiatsii kardiolohiv Ukrainy. 2016; 11–7. [in Ukrainian]
- Nykyforov VS, Marsalskaia OA, Metso KV, Palahutyn MA. Arteryalnaya hypertenziya i narushenyiya rytma serdtsa. Zdorovye – osnova chelovecheskogo potentsiala: problemy i puti ikh resheniya. 2016. 2; 594–96. [in Russian]
- Sirenko YuM. Recomendatsii ESC I ESH z likuvannya arterialnoyi hipertenziyi. K.: Zaslavskyi OYu. 2019; 22–23. [in Ukrainian]
- Trybrat TA, Shut SV, Trybrat AA, Kazakov YuM. Shliakhy korektsiyi asotsiiovanoho metabolichnoho syndromu u khvorykh na hipertonichnu khvorobu. Visnyk problem biolohiyi i medytsyny. 2018; 1 (142): 197–201. [in Ukrainian]
- Dangle PP, Ayyash O, Kang А. Cystatin C-calculated glomerular filtration rate-a marker of early renal dysfunction in patients with neuropathic bladder. Urology. 2017; 100: 213–17. https://doi.org/10.1016/j.urology.2016.08.011
- Hoogendijk MG, Geczy T, Yap S, Szili-Torok T. Pathophysiological mechanism of premature ventricular complexes. Front Physiol. 2020; 11: 406. https://doi.org/10.3389/fphys.2020.00406
- Hu G, Wang Z, Zhang R, Sun W, Chen X. The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review. Front Physiol. 2021; 12. https://doi.org/10.3389/fphys.2021.632886
- Ivankova AV, Kuzminova NV, Lozinsky SE, Havryliuk AO, Knyazkova II, Ivanova EI. Peculiarities of daily ECG changes in patients with essential hypertension of the second stage. World of medicine and biology. 2021; 1 (75): 59–63. https://doi.org/10.26724/2079-8334-2021-1-75-59-63
- Kuzminova NV, Ivankova AV, Ivanov VP, Lozinsky SE, Knyazkova II, Gavriluk AO. Daily blood pressure pattern disorders in patients with stage II essential hypertension and frequent premature beats. World of medicine and biology. 2020; 1(71): 72–7. https://doi.org/10.26724/2079-8334-2020-1-71-72-77
- Marcus GM. Evaluation and Management of Premature Ventricular Complexes. Circulation. 2020; 141 (17): 1404–18. https://doi.org/10.1161/CIRCULATIONAHA.119.042434
- Purmah Y, Proietti M, Laroche C, Mazurek M, Tahmatzidis D, Boriani G. [et al.] EORP-AF General Pilot Registry Investigators. Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. Europace. 2018; 20 (2): 243–52. https://doi.org/10.1093/europace/euw421
- Tian Y, Chen R, Jiang Y, Bai B, Yang T, Liu H. The Protective Effects and Mechanisms of Apelin/APJ System on Ischemic Stroke: A Promising Therapeutic Target. Frontiers in neurology. 2020; 11: 75. https://doi.org10.3389/fneur.2020.000755
- Yang S, Song L, Zhao L, Dong P, Lai L, Wang H. Predictive value of cystatin C in people with suspected or established coronary artery disease: A meta-analysis. Atherosclerosis. 2017; 263: 60–7. https://doi.org/10.1016/j.atherosclerosis.2017.05.025
- Zaki M, Kamal S, Ezzat W, Hassan N, Yousef W, Ryad H. [et al.] Serum apelin levels and metabolic risk markers in obese women. J Genet Eng Biotechnol. 2017; 15 (2): 423–29. https://doi.org10.1016/j.jgeb.2017.05.002
- Zhu Z, Zhong C, Xu T, Wang A, Peng Y, Xu T. [et al.] Prognostic significance of serum cystatin C in acute ischemic stroke patients according to lipid component levels. Atherosclerosis. 2018; 274: 146–51. https://doi.org/10.1016/j.atherosclerosis.2018.05.015
|
| Publication of the article |
«World of Medicine and Biology» №1(79), 2022 year, 085-090 pages, index UDK 616.12-008.318.4: 616.12-008.331.1 |
| DOI |
10.26724/2079-8334-2022-1-79-85-90 |
